Acelyrin Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Selling, General & Admin	66.18	13.55	3.56
Research & Development	355.89	55.63	38.23
Operating Expenses	422.06	69.18	41.79
Operating Income	-422.06	-69.18	-41.79
Other Expense / Income	-40.42	-4.41	0.05
Pretax Income	-381.64	-64.77	-41.84
Net Income	-381.64	-64.77	-41.84
Shares Outstanding (Basic)	70	2	1
Shares Outstanding (Diluted)	70	2	1
Shares Change	4410.31%	126.58%	-
EPS (Basic)	-5.43	-41.59	-60.87
EPS (Diluted)	-5.43	-41.59	-60.87
Free Cash Flow	-172	-61.52	-4.98
Free Cash Flow Per Share	-2.45	-39.50	-7.24
EBITDA	-381.37	-64.77	-41.84
Depreciation & Amortization	0.27	0	0
EBIT	-381.64	-64.77	-41.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).